Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy
Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy have?
Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy has 84 citations in the OpenAlex counts ScholarIQ stores.
When was Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy published?
Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy has 2021 year in the ScholarIQ index.
What is the open-access status of Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy?
Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy has gold oa status in the ScholarIQ index.
What is the DOI of Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy?
The DOI for Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy is on the source record.
What is the PMID of Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy?
The PMID for Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy is on the source record.
What is the OpenAlex record for Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy?
The OpenAlex for Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy is on the source record.